GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Institutional Ownership

Cosmo Pharmaceuticals NV (XSWX:COPN) Institutional Ownership : 12.33% (As of Dec. 14, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cosmo Pharmaceuticals NV's institutional ownership is 12.33%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cosmo Pharmaceuticals NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cosmo Pharmaceuticals NV's Float Percentage Of Total Shares Outstanding is 0.00%.


Cosmo Pharmaceuticals NV Institutional Ownership Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Institutional Ownership Chart

Cosmo Pharmaceuticals NV Historical Data

The historical data trend for Cosmo Pharmaceuticals NV can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 11.86 11.86 12.06 12.00 12.19 12.03 12.15 12.30 12.66 12.33

Cosmo Pharmaceuticals NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cosmo Pharmaceuticals NV Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV Headlines

No Headlines